Pharmacologic and Interventional Strategies for Stroke Prevention in Atrial Fibrillation: Current Strategies & Future Directions

Accredited On-Demand Webcast
Jointly sponsored by the University of Cincinnati and Horizon CME

Presenter

Bradley P. Knight, MD, FACC, FHRS
Director of Cardiac Electrophysiology, Bluhm Cardiovascular Institute of Northwestern University
Professor of Medicine, Feinberg School of Medicine, Northwestern
University Chicago, IL

Target Audience

Cardiologists and other members of the cardiac care team such as Nurse Practitioners, Physician Assistants, etc.

Learning Objectives

List factors that increase the risk of stroke in patients with atrial fibrillation
Identify the benefits, risks and limitations of warfarin therapy and guidelines for its use in stroke prevention in patients with atrial fibrillation
Discuss the benefits and limitations of genetic testing for warfarin dosing
Describe the role of antiplatelet therapy for stroke prevention in atrial fibrillation and recognize emerging alternatives to warfarin
Describe non-pharmacologic strategies for the prevention of stroke in patients with atrial fibrillation

Activity Overview

To be eligible for documentation of credit, participants must participate in the full activity, complete the 10-question online post-test with a score of 70% or better, and complete the evaluation. Participants who successfully complete the post-test and evaluation questions online will receive a certificate of completion via email.

There is no fee associated with this activity.

Participants who have successfully completed the live version of this activity are not eligible to receive credit for this enduring material.

Release Date: March 1, 2010
Expiration Date: March 1, 2011
Estimated time to complete: 1.25 hours

For questions regarding this educational activity, please contact Horizon CME at 503-775-5799.

Accreditation

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the University of Cincinnati and Horizon CME. The University of Cincinnati is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The University of Cincinnati designates this educational activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation.

Planning Committee

The planning committee comprises Gregory W. Albers, MD, Mark J. Alberts, MD, Bradley P. Knight, MD, Gene Y. Sung, MD; Brian Lee, PharmD, Sara Ogdon, Horizon CME; Lynn Fischer, Kay Weigand, and Rick E. Ricer, MD, University of Cincinnati.

Faculty Financial Disclosures

The University of Cincinnati is committed to resolving all conflict of interest issues which may arise as a result of prospective faculty members' relevant relationships with drug or device manufacturers. The University of Cincinnati is committed to retaining only those speakers with financial interest conflicts that can be reconciled with the goals and educational integrity of the CME activity.

Faculty	Disclosure(s)
Gregory W. Albers, MD	Advisory Board - Boehringer Ingelheim Consultant - Lundbeck Research Grants - Boehringer Ingelheim
Mark J. Alberts, MD	Advisory Board - AGA Medical, AstraZeneca, BMS, Boehringer Ingelheim, Genentech, The Medicines Company, Pfizer, and sanofi-aventis Consultant - AGA Medical, AstraZeneca, BMS, Boehringer Ingelheim, EKR Therapeutics, Genentech, The Medicines Company, Pfizer, sanofi-aventis, and Takeda Pharma Research Grants - AGA Medical, AstraZeneca, BMS, Boehringer Ingelheim, EKR Therapeutics, Photo Thera, sanofi-aventis, and Schering-Plough Review Board - Mitsubishi Pharma America and Schering-Plough Speakers Bureau - Astra Zeneca, BMS, Boehringer Ingelheim, diaDexus, EKR Therapeutics, Genentech, The Medicines Company, Medscape, and sanofi-aventis
Bradley P. Knight, MD, FACC, FHRS	No Relevant Relationships
Gene Y. Sung, MD, MPH	Research Grants - PDL Biopharma and The Medicines Company Speakers Bureau - Boehringer Ingelheim, Genentech, EKR Therapeutics, and Ferrer

Off-Label Disclosure

Faculty members are required to inform the audience when they are discussing off-label, unapproved uses of devices and drugs. Physicians should consult full prescribing information before using any product mentioned during this educational activity.

Dr. Knight will be discussing the off-label/unapproved uses for the following drugs and/or devices: combination of clopidogrel and aspirin, dabigatran, and the Watchman Left Atrial Appendage Closure Device.

Disclaimer

The opinions expressed during the educational activity are those of the faculty and do not necessarily represent the views of the University of Cincinnati. The information is presented for the purpose of advancing the attendees' professional development.

Planning Committee Disclosures

Planning Committee Member	Disclosure(s)
Lynn Fischer Program Compliance Director, Live Programs Office of Continuing Medical Education University of Cincinnati	No Relevant Relationships
Brian Lee, PharmD Medical Director Horizon CME	No Relevant Relationships
Rick E. Ricer, MD Content Reviewer Professor, Department of Family Medicine University of Cincinnati College of Medicine	No Relevant Relationships
Kay Weigand Program Director Office of Continuing Medical Education University of Cincinnati College of Medicine	No Relevant Relationships

Grant Support

This program is supported by an educational grant from the Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership.

Access to Webcast

To access the webcast, click on the link below. Once you arrive in the webcast portal, you will be required to complete the registration page. Once you have registered, you will have access to view the webcast and complete the post-test and evaluation for CME credit.

Username
Password